Karolína Krátká

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Role of duodenal iron transporters and hepcidin in patients with alcoholic liver disease

Marketa Dostalikova‐Cimburova, Kamila Balušíková, Karolína Krátká et al. · Journal of Cellular and Molecular Medicine · 2014 · 51 citations · Full text

High prevalence of<i>HFE</i>gene mutations in patients with porphyria cutanea tarda in the Czech Republic

Karolína Krátká, Marketa Dostalikova‐Cimburova, Helena Michalíková et al. · British Journal of Dermatology · 2008 · 13 citations

Iron overload and HFE gene mutations in Czech patients with chronic liver diseases.

Marketa Dostalikova‐Cimburova, Karolína Krátká, Jaroslav Stránský et al. · PubMed · 2012 · 10 citations · Full text

Iron Metabolism, Genetics, Genetic Epidemiology +24